Previous 10 | Next 10 |
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023 PR Newswire EO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 ...
2023-04-14 17:30:31 ET Gainers: Elevation Oncology ( ELEV ) +23% . Kezar Life Sciences ( KZR ) +16% . Vimeo ( VMEO ) +5% . Karyopharm Therapeutics ( KPTI ) +4% . LivaNova ( LIVN ) +3% . Losers: Silence Therapeutics&...
Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023 PR Newswire - Company plans to highlight preclinical proof-of-concept data for EO-3021 in an oral presentation at the New Drugs on the Horizon special session ...
2023-03-09 09:19:41 ET Elevation Oncology press release ( NASDAQ: ELEV ): Q4 GAAP EPS of -$0.82 misses by $0.09 . As of December 31, 2022, the Company had cash, cash equivalents and marketable securities totaling $90.3 million, compared to $107.9 million as o...
Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023 Announced pipel...
Elevation Oncology to Participate at Upcoming Investor Conferences PR Newswire NEW YORK , March 1, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies ...
Elevation Oncology to Present at the SVB Securities Global Biopharma Conference PR Newswire NEW YORK , Feb. 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cance...
Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective ca...
Elevation Oncology ( NASDAQ: ELEV ) CEO Shawn Leland has resigned amid a company effort to realign resources and prioritize pipeline assets . The company is focusing its R&D efforts on EO-3021, an antibody-drug conjugate for gastrointestinal cancers. The candidate is expe...
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition PR Newswire Prioritizing the development of EO-3021, a potential best-in-class ADC targeting Claudin18.2, and additional pipeline programs including those thr...
News, Short Squeeze, Breakout and More Instantly...
Elevation Oncology Inc. Company Name:
ELEV Stock Symbol:
NASDAQ Market:
Elevation Oncology Inc. Website:
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference PR Newswire BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therap...
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements PR Newswire -- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan ; expect to announce initial safety and efficacy data by mid-3Q 2024, wi...
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 PR Newswire -- On-track to nominate development candidate in 2024 -- BOSTON , April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...